- Home
- RNA vs PTCT Comparison
RNA vs PTCT Comparison
Compare RNA & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNA | PTCT |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 5.3B |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | RNA | PTCT |
|---|---|---|
| Price | $71.76 | $77.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 17 |
| Target Price | $69.26 | ★ $73.76 |
| AVG Volume (30 Days) | ★ 2.9M | 2.3M |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 8.94 |
| Revenue | $20,868,000.00 | ★ $1,779,150,000.00 |
| Revenue This Year | $64.11 | $128.32 |
| Revenue Next Year | $37.25 | N/A |
| P/E Ratio | ★ N/A | $8.64 |
| Revenue Growth | ★ 106.27 | 97.54 |
| 52 Week Low | $21.51 | $35.95 |
| 52 Week High | $71.79 | $87.50 |
Technical Indicators
Market Signals| Indicator | RNA | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 77.56 | 54.29 |
| Support Level | $71.42 | $73.03 |
| Resistance Level | $71.76 | $79.03 |
| Average True Range (ATR) | 0.41 | 3.38 |
| MACD | -0.73 | -0.70 |
| Stochastic Oscillator | 88.32 | 29.37 |
Price Performance
Historical ComparisonAbout RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.